Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125724431 | 12572443 | 1 | I | 2016 | 20160609 | 20160719 | 20160719 | PER | US-ASTRAZENECA-2016SE64565 | ASTRAZENECA | 73.00 | YR | F | Y | 68.00000 | KG | 20160720 | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125724431 | 12572443 | 1 | PS | SEROQUEL XR | QUETIAPINE FUMARATE | 1 | Oral | AT NIGHT | U | 22047 | PROLONGED-RELEASE TABLET | ||||||||
| 125724431 | 12572443 | 2 | SS | SEROQUEL XR | QUETIAPINE FUMARATE | 1 | Oral | AT NIGHT | U | 22047 | PROLONGED-RELEASE TABLET | ||||||||
| 125724431 | 12572443 | 3 | SS | SEROQUEL XR | QUETIAPINE FUMARATE | 1 | Oral | AT NIGHT | U | 22047 | PROLONGED-RELEASE TABLET | ||||||||
| 125724431 | 12572443 | 4 | C | SYNTHROID | LEVOTHYROXINE SODIUM | 1 | Oral | 0 | 125 | UG | QD | ||||||||
| 125724431 | 12572443 | 5 | C | WELLBUTRIN XCL | 2 | Oral | 0 | 150 | MG | QD | |||||||||
| 125724431 | 12572443 | 6 | C | WELLBUTRIN XCL | 2 | Oral | 0 | 150 | MG | QD | |||||||||
| 125724431 | 12572443 | 7 | C | LORAZEPAM. | LORAZEPAM | 1 | Oral | 1.0MG UNKNOWN | 0 | 1 | MG | ||||||||
| 125724431 | 12572443 | 8 | C | LEXAPRO | ESCITALOPRAM OXALATE | 1 | Oral | 0 | 20 | MG | QD | ||||||||
| 125724431 | 12572443 | 9 | C | LEXAPRO | ESCITALOPRAM OXALATE | 1 | Oral | 0 | 20 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125724431 | 12572443 | 1 | Anxiety |
| 125724431 | 12572443 | 2 | Depression |
| 125724431 | 12572443 | 3 | Amnesia |
| 125724431 | 12572443 | 4 | Thyroid disorder |
| 125724431 | 12572443 | 5 | Depression |
| 125724431 | 12572443 | 6 | Anxiety |
| 125724431 | 12572443 | 7 | Anxiety |
| 125724431 | 12572443 | 8 | Depression |
| 125724431 | 12572443 | 9 | Anxiety |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125724431 | 12572443 | Asthenia | |
| 125724431 | 12572443 | Cheilitis | |
| 125724431 | 12572443 | Chills | |
| 125724431 | 12572443 | Cough | |
| 125724431 | 12572443 | Dysphagia | |
| 125724431 | 12572443 | Eyelid pain | |
| 125724431 | 12572443 | Fatigue | |
| 125724431 | 12572443 | Feeling cold | |
| 125724431 | 12572443 | Hyperhidrosis | |
| 125724431 | 12572443 | Lip ulceration | |
| 125724431 | 12572443 | Mouth ulceration | |
| 125724431 | 12572443 | Myalgia | |
| 125724431 | 12572443 | Off label use | |
| 125724431 | 12572443 | Oropharyngeal pain | |
| 125724431 | 12572443 | Product use issue | |
| 125724431 | 12572443 | Pruritus | |
| 125724431 | 12572443 | Pyrexia | |
| 125724431 | 12572443 | Rash | |
| 125724431 | 12572443 | Restlessness | |
| 125724431 | 12572443 | Skin discolouration | |
| 125724431 | 12572443 | Stomatitis | |
| 125724431 | 12572443 | Tooth infection | |
| 125724431 | 12572443 | Tooth loss | |
| 125724431 | 12572443 | Urticaria | |
| 125724431 | 12572443 | Vision blurred | |
| 125724431 | 12572443 | Weight increased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125724431 | 12572443 | 1 | 20160426 | 0 | ||
| 125724431 | 12572443 | 2 | 20160426 | 0 | ||
| 125724431 | 12572443 | 3 | 20160426 | 0 |